Literature DB >> 2658082

Serotherapy of cancer.

D T Harris1, M J Mastrangelo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2658082

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


× No keyword cloud information.
  5 in total

1.  Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody.

Authors:  A Hekman; A Honselaar; W M Vuist; J J Sein; S Rodenhuis; W W ten Bokkel Huinink; R Somers; P Rümke; C J Melief
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  The production of a bispecific anti-CEA, anti-hapten (4-amino-phthalate) hybrid-hybridoma.

Authors:  F Lloyd; M Goldrosen
Journal:  J Natl Med Assoc       Date:  1991-10       Impact factor: 1.798

3.  Adriamycin(hydrazone)-antibody conjugates require internalization and intracellular acid hydrolysis for antitumor activity.

Authors:  G R Braslawsky; K Kadow; J Knipe; K McGoff; M Edson; T Kaneko; R S Greenfield
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 4.  Targeting of superantigens.

Authors:  T Kalland; M Dohlsten; L Abrahmsén; G Hedlund; P Björk; P A Lando; A Sundstedt; E Akerblom; P Lind
Journal:  Cell Biophys       Date:  1993 Jan-Jun

5.  Targeting of stealth liposomes to erbB-2 (Her/2) receptor: in vitro and in vivo studies.

Authors:  D Goren; A T Horowitz; S Zalipsky; M C Woodle; Y Yarden; A Gabizon
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.